News
Melinda French Gates’ VC firm backs women’s health start-up Tia
The investment comes as the firm seeks to scale up its support for women-led businesses
Melinda French Gates’ venture capital firm will invest an undisclosed sum towards the California women’s health start-up Tia.
Pivotal Ventures aims to accelerate equality in the United States through investments, partnerships, and advocacy in areas where social progress has “stalled”.
With a commitment of US$1bn, the VC company’s goal is to expand women’s power and influence in the US.
Its undisclosed investment towards the San Francisco-based Tia comes as the firm seeks to scale up its support for women-led businesses.
Founded in 2017 by Carolyn Witte and Felicity Yost, Tia aims to bring a new standard of care for women for women across New York, Los Angeles, San Francisco and Phoenix.
Its “Whole Woman, Whole Life” care model currently provides virtual and in-person services, including primary care, mental health, and gynaecological care.
Research has shown that almost half of women in the US do not have a stable relationship with a primary care physician for routine preventive care.
“My vision is that every primary care provider starts delivering mental health as routine primary care and that every primary care provider clinic eventually looks and feels like Tia’s,” Tia co-founder and CEO, Carolyn Witte told Fast Company.
After opening its second Los Angeles-area clinic in Santa Monica, Tia plans on opening more centres across the US.
The investment, following a partnership with the healthcare company Cedars-Sinai in January, will bring the start-up’s total funding to approximately US$150m.
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Wellness4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Hormonal health3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Hormonal health5 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
News4 weeks agoVerdane invest in Clue to accelerate the future of women’s health






